TMCnet News
OTC Tip Reporter: YM BioSciences Inc. (NYSE Amex: YMI), RadNet, Inc. (NASDAQ: RDNT),(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:27122010 www.OTCtipReporter.com YM BioSciences Inc. (NYSE Amex: YMI), RadNet, Inc. (NASDAQ: RDNT), Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) Sign-Up for our FREE Stock Picks AND OUR AWARD WINNING NEWSLETTER at www.OTCtipReporter.com _______________________________________________________________________________ For a FREE Report Visit: www.OTCtipReporter.com YM BioSciences Announces Exercise of Full Over-Allotment Option for Total Net Proceeds of US $43.3 Million MISSISSAUGA, ON, Dec. 23 -- YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM) announced today that, in connection with its previously announced public offering for total net proceeds before expenses of US $37,650,000, the underwriters have exercised in full their Over-Allotment Option to purchase an additional 3,750,000 common shares of YM at US $1.60 per share for additional net proceeds of US $5,665,000. The underwriters are Roth Capital Partners, LLC, which acted as the sole book-running manager for the offering, JMP Securities and Rodman & Renshaw LLC, which acted as co-managers, and Bloom Burton & Co., which acted as financial advisor to YM BioSciences in connection with the offering. The Company intends to use the proceeds to fund its drug development activities and for general corporate purposes. The securities described above were offered and sold by the Company pursuant to a registration statement filed with the Securities and Exchange Commission (SEC), which became effective on December 1, 2010. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus, as supplemented, relating to the offering may be obtained at the Securities and Exchange Commission's website at http://www.sec.gov, or may be obtained from Roth Capital Partners, LLC Equity Capital Markets, 24 Corporate Plaza, Newport Beach, CA 92660, at 800-678-9147 and [email protected]. About YM BioSciences YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA). CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated. This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. _______________________________________________________________________________ For a FREE Report Visit: www.OTCtipReporter.com RadNet to Enter the Teleradiology and Remote Interpretation Business Through the Acquisition of Imaging On Call LOS ANGELES, Dec. 22, 2010 -- RadNet, Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 198 fully-owned and operated outpatient imaging centers, today reported it has executed a definitive agreement to acquire Imaging On Call, LLC for $5.5 million plus contingent compensation of up to an additional $2.5 million if Imaging On Call achieves certain 2011 performance milestones. Founded in 2002, Imaging On Call, headquartered in Poughkeepsie, New York, is a premier provider of high quality, cost effective emergent and non-emergent daytime and nighttime teleradiology interpretations delivered to radiology groups, hospitals and imaging centers. Imaging On Call's offerings include preliminary, final and subspecialty coverage over a range of imaging modalities including CT, MRI, Ultrasound, Nuclear Medicine and X-ray. Imaging On Call currently contracts with hospital-based and non-hospital based radiology groups, hospitals, imaging centers and research foundations, to whom it provides remote interpretation of diagnostic imaging exams. Imaging On Call is Joint Commission accredited for final and preliminary reads, and its currently contracted radiologists, the vast majority of whom are located in the United States, hold active licenses in 28 states and the District of Columbia. Howard G. Berger, MD, President and Chief Executive Officer of RadNet, explained, "Entering the billion dollar U.S. teleradiology business is a natural extension of many of RadNet's current activities and core competencies. For many years, our approximately 350 contracted radiologists have utilized remote reading capabilities to service our owned and operated facilities and hospital joint ventures. Utilizing teleradiology techniques have made them more efficient, cost-effective and more capable of delivering subspecialty expertise to the patients of our referring physician communities. It is natural that we would begin to offer these same capabilities to organizations outside of RadNet. The acquisition of Imaging On Call provides us the infrastructure, operational platform and customer relationships to succeed in providing these services. Because a majority of Imaging On Call's customers overlap RadNet's current operating regions in the northeastern United States, it is the ideal platform from which to grow." Dr. Berger added, "In particular, we believe Imaging On Call will be a key component of augmenting our strategies related to partnering with hospitals and Accountable Care Organizations in joint ventures, regardless of their geography. We are especially excited about being able to offer prospective hospital joint venture partners a portfolio of solutions which include various management services for outpatient and inpatient imaging operations, software solutions and professional radiology services, including teleradiology and on-site staffing." Dr. Berger continued, "When including all the physicians who comprise RadNet's contracted radiology groups, we believe we now have more potential teleradiology resources under one umbrella than any other company across the globe. Furthermore, like our recently acquired eRAD software solutions business and related software development projects, our entry into providing teleradiology services helps us diversify our offerings into areas of diagnostic imaging which require less capital investment." Michael Lampron, Chief Executive Officer of Imaging On Call, stated, "We are very excited about being part of the RadNet family. Among the many accomplishments of Imaging On Call over the last eight years has been the building of an operating platform which is characterized by great technology, excellent customer service, a marquee customer list and dedicated and committed employees. We believe that the resources that RadNet bears will further strengthen Imaging On Call's stability and growth prospects. This transaction should provide significant benefits to our existing customers, contracted radiologists and employees." The acquisition of Imaging On Call is expected to close on or around December 31, 2010, and is subject to a vote of Imaging On Call's LLC membership interest holders approving the transaction. Imaging On Call is expected to initially add approximately $10 million of revenue to RadNet on an annual basis. About RadNet, Inc. RadNet, Inc. is a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 198 fully-owned and operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey and New York. Together with affiliated radiologists, and inclusive of full-time and per-diem employees and technologists, RadNet has over 4,300 employees. For more information, visit http://www.radnet.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the Company's ability to successfully integrate acquired operations, achieve cost savings, develop new and useful software products and successfully market those products, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect the Company's business and its financial results are detailed in its most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. _______________________________________________________________________________ For a FREE Report Visit: www.OTCtipReporter.com Threshold Pharmaceuticals Announces Promising Early Phase 1 Clinical Trial Results in Patients With Advanced Leukemias Company Also Starts Preclinical Leukemia Collaboration With MD Anderson Cancer Center REDWOOD CITY, Calif., Dec. 22, 2010 -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced a preclinical collaboration with the MD Anderson Cancer Center and early Phase 1 clinical trial results of TH-302 in patients with advanced leukemias, which is also taking place at MD Anderson. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. The objectives of the Phase 1 trial are to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety, tolerability, clinical activity and pharmacokinetics of TH-302 in patients with advanced leukemia. Eleven patients with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) have been enrolled in the trial to date. The starting dose in the trial was 120mg/m2 daily for 5 days of a 21-day cycle. The second dose cohort was treated with TH-302 at a dose of 170mg/m2 and the third dose cohort has completed enrollment at 240mg/m2. The dose of TH-302 will continue to be escalated until the MTD is established. To date no DLTs have been reported in any of the dose cohorts. Preliminary efficacy assessments have demonstrated activity in multiple subjects with relapsed/refractory AML and ALL as evidenced by stabilization or reduction of bone marrow blast counts. "In the initial three dosing cohorts, TH-302 has been well tolerated with no significant drug related toxicities," said Dr. Deborah Thomas, M.D., Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. "We look forward to further assessing the safety and efficacy of TH-302." The preclinical collaboration is being conducted with Dr. Marina Konopleva, M.D., Ph.D, Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. The research collaboration will focus on characterizing the therapeutic efficacy of TH-302 as monotherapy and in combination with conventional chemotherapeutics in both in vitro and in vivo models of leukemia. "There is already a strong preclinical rationale to evaluate TH-302 in leukemia patients," said Dr. Charles Hart, Ph.D., Threshold's Vice President of Biology. "While we continue to explore the proof of concept in the ongoing human clinical trial, we also want to fortify the preclinical basis for selectively targeting the hypoxic niches in leukemic bone marrow as a therapeutic strategy. Greater understanding may lead to the identification of specific patient subgroups most likely to benefit and the identification of biomarkers for patient selection." Clinical Trial Design Approximately 40 patients with advanced leukemias or other severe hematologic disorders affecting the marrow are planned to enroll in the clinical trial at the MD Anderson Cancer Center. Patients with relapsed/refractory chronic lymphocytic leukemia (CLL), ALL, AML, advanced phase chronic myelogenous leukemia (CML), high risk myelodysplastic syndrome (MDS) or advanced myelofibrosis (MF) will be eligible for the trial. The initial dose escalation phase of the trial will enroll cohorts of up to 6 patients per dose. All doses of TH-302 are being administered as a 30-60 minute intravenous infusion daily for 5 days every 21 days. The primary objective of the dose escalation component of the study is to establish the MTD and dose limiting toxicities of TH-302 when administered daily for 5 days. The dose escalation phase of the trial will enroll up to 30 patients. Once the MTD has been established, up to 10 additional patients will be enrolled at the MTD in the dose expansion component of the trial. The objective of the dose expansion is to further assess the clinical activity of TH-302 in this population. Patients for whom no curative therapy exists are eligible for this trial. Clinical Rationale TH-302 is selectively activated in the hypoxic microenvironment of tumors. Preclinical data support the hypothesis that TH-302 targets hypoxic regions of solid tumors. Preclinical data from the Vrije Universiteit in Brussels and Threshold Pharmaceuticals has shown diseased marrow to be significantly more hypoxic than non-diseased marrow and that TH-302 has activity in multiple myeloma cells in vivo and in vitro. Additionally, data from MD Anderson demonstrated the marked expansion of the hypoxic bone marrow areas in diseased mice with ALL. These preclinical results suggest that an agent that selectively targets the hypoxic regions of tumors may be useful in treating advanced leukemias. About Advanced Leukemia Advanced leukemia is an acute or chronic cancer involving the blood-forming tissues in the bone marrow. It may be classified as myeloid or lymphoid. According to the American Cancer Society, leukemia accounts for 3% of all cancers diagnosed in the United States in 2009, and about 22,000 people die annually of some form of leukemia. Chronic lymphocytic leukemia is the most common leukemia in the United States, accounting for a third of cases diagnosed each year. Acute myelogenous leukemia accounts for approximately 30% of diagnosed adult leukemias. About TH-302 Threshold has evaluated TH-302 in over 400 patients with various solid tumors. In addition to the advanced leukemia trial, the Company has several ongoing clinical trials including, but not limited to, a controlled Phase 2 trial of TH-302 in combination with gemcitabine in patients with advanced pancreatic cancer and a Phase 1/2 study evaluating TH-302 in combination with doxorubicin in soft tissue sarcoma. About Threshold Pharmaceuticals Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com). Forward-Looking Statements Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding TH-302 and its potential therapeutic uses and benefits. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to continue to successfully enroll patients in clinical trials, whether the Company's clinical trials will show results predicted by the Company's pre-clinical trials or confirm the results of earlier trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and any unanticipated or increased side-effects observed in patients receiving TH-302. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on November 4, 2010 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release. _______________________________________________________________________________ For a FREE Report Visit: www.OTCtipReporter.com About OTCtipReporter.com www.OTCtipReporter.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. www.OTCtipReporter.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity. To subscribe to this free service, visit the OTCtipReporter Stock Report home page at http://www.OTCtipReporter.com and Sign up Free For "Daily Stock Alerts". Join us at http://www.OTCtipReporter.com for a complimentary subscription to the most exciting online financial newsletter. To feature your publicly traded company in our alerts, email us at: [email protected] Disclaimer: Verify all claims and do your own due diligence. OTCtipReporter.com profiles are not a solicitation or recommendation to buy, sell or hold securities. OTCtipReporter.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. OTCtipReporter.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), OTCtipReporter.com is owned and operated by OTCtipReporter.com. Neither OTCtipReporter.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this press-release, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since OTCtipReporter.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in OTCtipReporter.com statements and opinions and such statements and opinions cannot be considered independent. OTCtipReporter.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. OTCtipReporter.com services are often paid for using free-trading shares. OTCtipReporter.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. Visit us for a full Disclaimer at: http://www.otctipreporter.com/disclaimer.htm To feature your publicly traded company in our alerts, email us at: [email protected] ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). (c) 2010 M2 COMMUNICATIONS |